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Photodynamic therapy (PDT) has been proven effective for treatment of several types of cancer. Photodynamic therapy alone,
however, attains limited cures with some tumours and there is need for its improved efficacy in such cases. Sphingolipid (SL)
analogues can promote tumour response in combination with anticancer drugs. In this study, we used mouse SCCVII squamous cell
carcinoma tumours to determine the impact of Photofrin-PDT on the in vivo SL profile and the effect of LCL29, a C6-pyridinium
ceramide, on PDT tumour response. Following PDT, the levels of dihydroceramides (DHceramides), in particular C20-DHceramide,
were elevated in tumours. Similarly, increases in DHceramides, in addition to C20:1-ceramide, were found in PDT-treated SCCVII
cells. These findings indicate the importance of the de novo ceramide pathway in Photofrin-PDT response not only in cells but also in
vivo. Notably, co-exposure of SCCVII tumours to Photofrin-PDT and LCL29 led to enhanced tumour response compared with PDT
alone. Thus, we show for the first time that Photofrin-PDT has a distinct signature effect on the SL profile in vitro and in vivo, and that
the combined treatment advances PDT therapeutic gain, implying translational significance of the combination.
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Ceramide mimetics and drugs targeting sphingolipid (SL)
metabolism have made major advances towards cancer treatment
(Fox et al, 2006; Zeidan and Hannun, 2007). To overcome the low
solubility of ceramide, cationic pyridinium ceramide analogues
have been developed, which are water soluble (Szulc et al, 2006).
These analogues have effective anticancer activity at relatively low
concentrations (Novgorodov et al, 2005; Rossi et al, 2005; Dindo
et al, 2006; Senkal et al, 2006; Zeidan and Hannun, 2007; Dahm
et al, 2008). LCL124, alone or in combination with the
chemotherapeutic agent gemcitabine, inhibits substantially the
growth of human head and neck squamous cell carcinomas in vitro
and in vivo (Senkal et al, 2006). LCL30 has potent antitumour
activity against colorectal cancer in mice (Dahm et al, 2008).
The oxidative stress inducer photodynamic therapy (PDT) uses
a photosensitiser, visible light and oxygen to generate reactive
oxygen species that can destroy malignant cells by apoptosis
(Dougherty et al, 1998; Miller et al, 2007). We have shown in Jurkat
cells with downregulated sphingomyelin synthase that an
enhanced accumulation of ceramide and dihydroceramide
(DHceramide) correlates with the promotion of apoptosis post-
Pc 4-PDT (Separovic et al, 2008). We have also demonstrated that
the combination of Pc 4-PDT with exogenous C16-ceramide
increases mitochondrial depolarisation and apoptosis in Jurkat
cells (Dolgachev et al, 2003). There is need to verify the relevance
of our cell culture findings in tumour models. A novel effective
ceramide mimetic LCL29 (Szulc et al, 2006; Bielawska et al, 2008),
a structural analogue of LCL124, was used to test its ability to
enhance the response of mouse SCCVII squamous cell carcinomas
to Photofrin-PDT. The photosensitiser Photofrin was used because
of its clinical relevance as it is the only photosensitiser approved
by the Food and Drug Administration for cancer treatment in the
United States. The main objectives of this study were (i) to
determine signature effects of Photofrin-PDT on endogenous
ceramide and DHceramide in SCCVII cells and tumours and (ii) to
determine the therapeutic effect of the combination PDTþLCL29
in SCCVII tumours.
MATERIALS AND METHODS
Tumour-related cell model and PDT treatment
As shown earlier (Cecic and Korbelik, 2006), mouse SCCVII
squamous carcinoma cells were grown in Alpha Minimal Essential
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sMedium (Sigma-Aldrich, St Louis, MO, USA) containing 10% heat-
inactivated foetal bovine serum (Hyclone, Logan, UT, USA). The
photosensitiser Photofrin (Axcan Pharma, Mont-Saint-Hilaire, QC,
Canada) was dissolved in 5% dextrose. For the experiment,
following overnight incubation with Photofrin (20mlml
 1), cells
(4.5 10
6) were irradiated at 0.5 or 1mJcm
 2 using a beam of
630±10nm. To generate the beam, a 600-W quartz-halogen light
source with infrared radiation reduced by a 10-cm layer of water
and 850-nm cutoff filter was used. The bandwidth was further
confined to 630±10nm by a narrowband-interference filter (Oriel
Instruments, Stratford, CT, USA). Two or four hours after PDT,
cells were collected for mass spectrometry (MS).
Tumour model and PDT treatment
As described earlier (Sun et al, 2002), female C3H/HeN mice were
implanted with syngeneic SCCVII squamous cell carcinoma
tumours (Khurana et al, 2001) by a subcutaneous injection of
1 10
6 SCCVII cells at a lower dorsal site. After 7–8 days, the
tumours reached a size of 6–8mm in largest diameter. At that
point treatment began. The cohort of SCCVII tumour-bearing mice
was divided into groups for various treatments. Tumour growth
was monitored and recorded by measuring three orthogonal
tumour diameters (a, b and c) using a caliper. Tumour volume (V)
was calculated using the formula: V¼P ab c/6. The measure-
ment was taken every second day. Mice were killed before starting
to suffer from tumour burden, that is, at the point when tumour
size was 15mm in diameter. For PDT, tumours were treated 24h
after photosensitiser administration with light produced by an FB-
QTH high-throughput illuminator (Sciencetech, London, ON,
Canada). Light was delivered through a 630±10-nm interference
filter for superficial tumour illumination with a fluence rate of
80–90mWcm
 2. During treatment of tumours with light, the mice
were immobilized with metal holders. Thereafter, the mice were
monitored up to 14 days post-therapy and the presence of tumours
or their absence recorded every 2 days. The ceramide analogue D-
erythro-2-N-[60-(100-pyridinium)-hexanoyl]-sphingosine bromide
(LCL29, also known as C6-pyridinium ceramide) was obtained
from Avanti Polar Lipids (Alabaster, AL, USA). For experiments,
LCL29 was dissolved in distilled water and injected intraperitone-
ally (20mgkg
 1) daily over a period of 7 days. The first injection
was administered 2h before PDT light treatment. Blood obtained
from mice by cardiac puncture was collected into EDTA-contain-
ing tubes, and plasma samples together with samples of tumour
tissue homogenates were analysed for the SL profile using MS. The
procedures with mice were approved and overseen by the Animal
Care Committee of the University of British Columbia.
Measurement of SLs by electrospray ionisation/double MS
As we have shown earlier (Separovic et al, 2007; Separovic
et al, 2008) following extraction, SLs were separated by high-
performance liquid chromatography, introduced to electrospray
ionisation source and then analysed by double MS using TSQ 7000
triple quadrupole mass spectrometre (Thermo-Fisher Scientific,
San Jose, CA, USA) which allows the simultaneous determination
of various SLs, including various ceramide and DHceramide
species, dihydrosphingosine (DHsphingosine), sphingosine and
sphingosine-1-phosphate (S1P) (Bielawski et al, 2006). Specifically,
samples obtained from cells or tissues were fortified with the
internal standards (C17-base-D-e-sphingosine, C17-sphingosine-1-
phosphate, N-palmitoyl-D-e-C13-sphingosine and C17-D-e-sphin-
gosine) and extracted with ethyl acetate/isopropanol/water (60/30/
10, v/v). After evaporation and reconstitution in methanol,
samples were injected into the HP1100/TSQ 7000 LC/MS system
and gradient eluted from the BDS Hypersil C8, 150 3.2mm, 3-mm
particle size column, with 1mM methanolic ammonium formate/
2m M aqueous ammonium formate mobile phase. Peaks corre-
sponding to the target analytes and internal standards were
collected and processed using the Xcalibur software system.
Quantitative analysis is based on the calibration curves generated
by spiking an artificial matrix with known amounts of the target
analyte synthetic standards and an equal amount of the internal
standards. For the calibration curves, the target analyte/internal
standard peak area ratios are plotted against analyte concentra-
tions. The target analyte/internal standard peak area ratios from
the samples are similarly normalised to their respective internal
standards and compared with the calibration curves, using a linear
regression model.
Statistical analysis
For statistical analysis of MS data, unless indicated otherwise, the
mass of SLs in pmolmg
 1 was log2 transformed to improve the
normality of the distributions and allow computation of more
robust means and standard deviations. As 26–29 SLs were
measured and tested for differences at the same time, besides
nominal P-values obtained by t-test, adjusted P-values (Po0.1)
using the false discovery rate (FDR) method were used to infer
significance (Benjamini and Hochberg, 1995). The R statistical
environment (www.r-project.org) was used for all computations.
For in vitro studies, the analysis of the interaction between
Photofrin and light dose, in addition to assessing the effect of time,
was performed by linear models (Wilkinson and Rogers, 1973). For
MS in vivo studies, a two-tailed t-test was employed to compare
concentration levels of SLs between treatment groups, as well as
to test whether fold changes for the entire family of SLs
(e.g., ceramides) were different than 1. To assess the effect of the
combined treatment on tumour reduction, a linear mixed-effects
model was used (Pinheiro and Bates, 2000).
Table 1 Statistical analysis of SL responses to PDT in SCCVII cells
Fold increase *P-value **P-value
C14-Cer 3.1 0.154 0.222
C16-Cer 3.7 0.063 0.136
C18-Cer 5.1 0.041 0.112
C18:1-Cer 4.0 0.028 0.104
C20-Cer 6.1 0.046 0.112
C20:1-Cer 7.3 0.016 0.088
C22-Cer 4.3 0.146 0.222
C22:1-Cer 6.5 0.127 0.222
C24-Cer 3.4 0.370 0.400
C24:1-Cer 3.7 0.278 0.357
C26:1-Cer 2.5 0.153 0.222
C14-DHCer 10.5 0.005 0.059
C16-DHCer 11.8 0.003 0.059
C18-DHCer 3.4 0.266 0.357
C18:1-DHCer 9.6 0.017 0.088
C20-DHCer 2.4 0.309 0.365
C20:1-DHCer 4.6 0.099 0.197
C22-DHCer 5.3 0.007 0.059
C22:1-DHCer 8.9 0.289 0.357
C24-DHCer 5.8 0.047 0.112
C24:1-DHCer 3.3 0.035 0.112
C26:1-DHCer 1.3 0.825 0.858
DHSph 6.3 0.369 0.400
Sphingosine 1.0 0.995 0.995
DHS1P 9.8 0.026 0.104
S1P 6.9 0.145 0.222
C14-Cer¼C14-ceramide; C14-DHCer¼C14-DHceramide; DHSph¼DHsphingo-
sine; DHS1P¼DHsphingosine-1-phosphate; S1P¼sphingosine-1-phosphate. After
overnight incubation with Photofrin (20mgml
 1), SCCVII cells were exposed to light
(0.5 or 1.0mJcm
 2) and incubated at 37
oC for 4h before collection for MS analysis.
Fold increase refers to an increase in the level of each SL after PDT per 1mJcm
 2 of
light. *P-value, nominal P-value. **P-value, FDR-adjusted P-value. Bold type values
indicate statistical significance.
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sRESULTS AND DISCUSSION
Signature effects of Photofrin-PDT on the SL profile
of in vitro cultured SCCVII cells
SCCVII cells were exposed to low and high PDT doses
corresponding to BLD30 and LD80, respectively (Cecic and
Korbelik, 2006), incubated for 2 or 4h at 371C, and collected for
MS. Neither Photofrin nor light alone had significant effects
on basal levels of SLs (not shown). Dose responses of SLs to
PDT were statistically evaluated against their corresponding
controls. The levels of C20:1-ceramide, C14-, C16-, C18:1- and
C22-DHceramide significantly rose to 7.3-, 10.5-, 11.8-, 9.6- and
5.3-fold, respectively, by 4h per 1mJcm
 2 of light fluence (Table1).
A dose-dependent increase in C22-DHceramide is shown in Figure 1.
Globally, the levels of ceramides and DHceramides significantly
increased to 4.3- and 5.0-fold of their corresponding controls per
1mJcm
 2 of light fluence (not shown). Thus, there was global and
selective increase in ceramides and DHceramides per unit of PDT
light dose.
The levels of other SLs were also evaluated with respect to PDT
dose. DHsphingosine-1-phosphate was increased 9.8-fold per unit
of PDT dose (Table 1). Although the nominal P-value indicates a
significant change, the chosen FDR value does not, which could be
a false-negative result. There was no significant effect of PDT dose
on the levels of DHsphingosine, sphingosine or S1P (Table 1).
Time dependence of the SL response to PDT was also analysed.
Individual ceramides did not show significant time-dependent
changes post-PDT. However, there was a significant, 12.5% average
increase per hour post-PDT in the levels of all 11 ceramides. The
chance that this was a random event is only 0.00048 (not shown).
Other SLs, including DHceramides, individually or globally, did
not show significant changes over time post-PDT (not shown).
Overall, these are important findings because they demonstrate
that the accumulation of ceramide and DHceramide is not only
limited to Pc 4-PDT, as we have shown earlier (Separovic et al,
2007; Separovic et al, 2008), but can also be evoked after Photofrin-
PDT. These data also demonstrate the involvement of the de novo
ceramide pathway after photodamage.
In vivo basal SL profile shows the prevalence of ceramides
Ceramides and DHceramides detected in untreated SCCVII
tumours comprised 89 and 11% of the total SL mass, respectively
(Figure 2A). In the plasma of mice bearing these tumours,
ceramides, DHceramides and S1P comprised 56, 14 and 25% of the
total SL mass at rest, respectively (Figure 2A). Virtually all S1P was
found in the plasma. Vascular endothelium has been suggested to
contribute to mouse plasma S1P (Venkataraman et al, 2008).
The levels of ceramides and DHceramides that comprise 10% or
more of the total corresponding SLs are depicted in Figure 2B. The
most abundant ceramides in growing untreated SCCVII tumours
were C16-, C24- and C24:1-ceramide comprising 13, 36 and
40% of total ceramides, respectively (Figure 2B). Interestingly,
C16-ceramide, not C24:1-ceramide, is the most abundant ceramide
in human head and neck squamous carcinomas (Koybasi et al,
2004). One reason for the discrepancy could be that non-tumour
cells associated with these tumours are different.
In plasma, the levels of C16-ceramide were restricted below 1%
of total plasma ceramides. Plasma C24-ceramide comprised nearly
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Figure 2 SL levels in untreated SCCVII tumours and host plasma. Using
cardiac puncture, blood was collected into EDTA tubes. Tumours were
excised and their homogenates as well as plasma samples were processed
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tumours and plasma, respectively. (B) The levels of most abundant
ceramides and DHceramides (pmolmg
 1) in untreated SCCVII tumours
and host plasma. The data for each SL are expressed as the mean±s.e.m.
(n¼3–4).
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Figure 1 Photofrin-PDT increases C22-DHceramide in SCCVII cells.
After overnight incubation with Photofrin (20mgml
 1), cells were
irradiated at 0.5 (low) or 1mJcm
 2 (high) light dose, incubated at 371C
for 2 or 4h and collected for MS analysis. Con, corresponding controls.
A three-dimensional plot of C22-DHceramide levels as a function of
treatment conditions is shown. Unlike Photofrin or light alone, PDT
triggered a significant increase in C22-DHceramide levels.
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s50% of total ceramides. Comparative levels of tumour and plasma
C16-DHceramide followed the same pattern as C16-ceramide
(Figure 2B). The very-long fatty acyl chain DHceramides, C22-,
C22:1- and C24-DHceramide were among the most abundant in
both tumours and plasma. Overall, ceramides and DHceramides
with long and very-long fatty acyl chains were the most abundant
species in these tissues.
Global increase in tumour DHceramides after Photofrin-
PDT
SCCVII tumours were treated with a therapeutic dose of Photofrin-
PDT (Korbelik and Cecic, 2008). Tumour and plasma SL profiles
were identified by MS (Figure 3). Among plasma ceramides,
only the levels of C24-ceramide were 29% lower after PDT
compared with Photofrin alone (Figure 3B). Notably, following
PDT the levels of tumour C20-DHceramide increased to 5.4-fold
of Photofrin alone (Figure 3C). There were no significant
differences in the levels of specific tumour ceramides or
plasma DHceramides after PDT compared to Photofrin alone
(Figures 3A and D).
In addition, overall fold changes were calculated for averages of
all ceramides or DHceramides after PDT relative to averages of all
corresponding SLs in untreated or Photofrin-treated mice.
Compared with untreated controls, the levels of total tumour
ceramides were reduced by 67 and 38% after Photofrin and PDT,
respectively (Figure 4A). Compared with Photofrin, a 21%
attenuation of tumour ceramide response to PDT was significant
(Figure 4B). A significant 1.3-fold total increase in plasma
ceramides was observed following either Photofrin alone or PDT
(Figures 4A and B).
Relative to untreated controls, a 34% total decrease in
tumour DHceramides was observed post-Photofrin (Figure 4A).
In contrast, exposure of mice to PDT led to a 15% total increase in
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Figure 3 Mass spectrometric analysis reveals distinct signature effects on the in vivo SL profile after Photofrin-PDT. (A and B) The levels of tumour and
plasma ceramides, respectively. (C and D) The levels of tumour and plasma DHceramides, respectively. Photofrin (10mgkg
 1) was injected i.p. 1 day before
exposure of SCCVII-bearing mice to light (150Jcm
 2). Four hours after PDT, mice were killed. For other details, see Figure 2. Each experimental group
consisted of four mice. In the plots, for y axis, log scale is used. The boxes contain 50% of the data and the median value is shown as the horizontal thick line
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stumour DHceramides relative to untreated controls (Figure 4A).
Thus, compared with Photofrin alone, there was an overall
significant 1.6-fold increase in tumour DHceramides post-PDT
(Figure 4B). Total increases in plasma DHceramides were similar
in mice exposed to either treatment (Figures 4A and B).
No significant effect on tumour S1P levels was observed after
PDT. In plasma, Photofrin alone or PDT decreased S1P levels by
31% so that there was no difference between the two (not shown).
Neither tumour nor plasma sphingosine levels were significantly
affected by PDT (not shown).
In summary, these are significant data not only because they
confirm our cell culture findings but also because they show for
the first time that a therapeutic dose of Photofrin-PDT triggers a
significant, potentially selective, build-up in tumour DHceramides,
supporting the involvement of the de novo ceramide pathway in
PDT in vivo response. Photofrin alone also affects the SL profile,
but the impact of PDT is distinctly different, particularly in
triggering more dramatic increases in DHceramide levels. The
effects of photosensitiser alone on SLs are expected to be less
pronounced, with more potent sensitising agents administered at
much lower doses than Photofrin.
Enhanced tumour response after Photofrin-
PDTþceramide analogue LCL29
To test whether the ceramide analogue LCL29 can improve PDT
tumour response, SCCVII tumours were treated with a moderately
therapeutic dose of Photofrin-PDTþnon-toxic dose of LCL29
(Senkal et al, 2006). LCL29 was administered daily over 7 days,
starting as the combination with PDT. As shown in Figure 5
(insert), LCL29 alone had no effect on tumour growth. Remark-
ably, growth retardation of mouse tumours attained by PDT was
enhanced by adjuvant LCL29 (Po0.012; Figure 5). An average of
24% decrease in tumour volumes was detected across all time
points. It is conceivable that this effect can be improved by
optimising LCL29 treatment protocol, for example, by escalating
LCL29 doses, and/or by other SL agents. These are important data
showing for the first time that PDT tumour response is promoted
by an SL-modulating agent.
This study demonstrates for the first time that Photofrin-PDT
has a definitive effect on the SL profile not only in SCCVII cells but
also in vivo. Specifically, DHceramides are elevated in vitro and in
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curves for individual tumours. Tumours in PDTþLCL29 group grew
slower than the majority of those in PDT-only group. On the basis of the
linear mixed-effects model, the difference between these two groups is
significant with Po0.012 (n¼7). Volume normalisation was performed by
dividing the tumour volume data by the tumour volume measured on day 0.
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stumours after PDT. These novel findings support the notion that
the de novo SL pathway is a PDT target. Others (Bose et al, 1995;
Perry et al, 2000; Charles et al, 2001; Min et al, 2007; Senkal et al,
2007; Wang et al, 2008) and we (Wispriyono et al, 2002; Dolgachev
et al, 2004; Dolgachev et al, 2005; Separovic et al, 2007; Separovic
et al, 2008) have shown the involvement of de novo SLs in response
to anticancer therapeutics. DHceramide synthase 1 (LASS1)/C18-
ceramide have been associated with chemotherapy-triggered
killing of human head and neck squamous cell carcinomas
(Senkal et al, 2007). We observed a significant increase in C18:
1-DHceramide, the product of DHceramide synthase 1. Our
findings in SCCVII cells support the notion that, besides
DHceramide synthase 1, other DHceramide synthases, such as
DHceramide synthase 2 and DHceramide synthase 4, might be
involved in increasing DHceramide levels after PDT. A marked
increase in tumour C20-DHceramide further supports the role of
DHceramide synthase 2 and DHceramide synthase 4, which have
specificity for C20–C26 and C20±2 fatty acyl CoA, respectively
(Pewzner-Jung et al, 2006; Laviad et al, 2008). These findings imply
that the accumulation of tumour DHceramide might serve as a
biomarker of tumour response to PDT and that targeting the de
novo ceramide pathway might be a strategy for drug development
to advance PDT tumour response.
Another key finding of this study is that co-exposure of SCCVII
tumours to Photofrin-PDT and LCL29 leads to enhanced retarda-
tion of tumour growth compared with Photofrin-PDT alone.
Similarly, LCL124, a structural analogue of LCL29, together with
the anticancer agent gemcitabine, effectively inhibits tumour
growth of human head and neck squamous cell carcinomas in
vivo (Senkal et al, 2006). Endogenous ceramide levels were not
changed after 24 days, that is, at the end of in vivo studies after
LCL124 or after the combination with gemcitabine (Senkal et al,
2006), suggesting no long-term effect of the treatments on
ceramide metabolism. Notably, LCL29 evokes a time-dependent
increase in total ceramide levels over 24h in MCF-7 cells (Szulc
et al, 2006). Selective increases in C16-, C14- and C18-ceramides
and decreases in C24- and C24:1-ceramides were observed (Szulc
et al, 2006). The signature effects of LCL29 alone or in combination
with Photofrin-PDT on the SL profile in SCCVII cells and tumours
remain to be determined.
In summary, this is the first report demonstrating that following
Photofrin-PDT, definitive changes in the SL profile in SCCVII cells
and tumours are triggered, and that tumour response is improved
after the combined treatment with Photofrin-PDTþceramide
analogue LCL29. Thus, our study validates the therapeutic efficacy
of LCL29 in combination with Photofrin-PDT. These findings
indicate that ceramide analogues hold the potential of a new class
of adjuvants for advancing PDT therapeutic successes.
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